SUPPLEMENTAL MATERIAL

Methods

A complete presentation of methods is given in reference 3. This includes a complete list of covariables that were included in the adjustments. These are repeated here:

For the efficacy endpoints: age, sex, body mass index, prior stroke/transient ischaemic attack, vascular disease (myocardial infarction, peripheral artery disease, carotid occlusive disease), chronic heart failure, hypertension, chronic obstructive pulmonary disease, diabetes mellitus, paroxysmal AF, diastolic blood pressure, creatinine clearance (Cockcroft–Gault), heart rate, and abstinence from alcohol use.

<u>For the safety endpoints:</u> age, sex, prior stroke/transient ischaemic attack, anaemia, prior gastrointestinal bleeding, chronic obstructive pulmonary disease, diastolic blood pressure, creatinine clearance (Cockcroft–Gault), platelets, albumin, and prior aspirin, vitamin K antagonist, or thienopyridine use.

Regarding patient selection, the following sections from reference 3 are relevant

Definitions and endpoints (from reference 3)

The case report form asked whether there was 'significant valvular disease,' and if so, it asked for 'valve location and abnormality' and 'etiology.' Thus, for the purpose of this study, any type of valvular lesion that did not meet the above exclusion criteria was included in SVD if it was considered to be significant by the recruiting physician(s) in order to reflect clinical practice (external validity).

Limitations (from reference 3)

The protocol did not include precise quantification of valve disease. However, the term 'significant' valvular lesion implied that the physician did not consider it as less than moderate. On the other hand, it could also not be of such haemodynamic significance that cardiac surgery would be necessary in the foreseeable future since this was an exclusion criterion. Thus, the majority of patient can be suspected to have had moderate valve disease.

Supplemental Table 1. Treatment comparisons for efficacy and safety endpoints among SVD subtypes and for no-SVD

patients.

1A. Event rates.

Outcomes	AS		MR or AR		No SVD	
	Rivaroxaban	Warfarin	Rivaroxaban	Warfarin	Rivaroxaban	Warfarin
	events/	events/	events/	events/	events/	events/
	100 pt-yrs	100 pt-yrs	100 pt-yrs	100 pt-yrs	100 pt-yrs	100 pt-yrs
	(total events)	(total events)	(total events)	(total events)	(total events)	(total events)
Efficacy outcomes						
Stroke or SE	4.74 [1.11,8.37] (9)	3.73 [0.75,6.71] (8)	1.70 [1.02,2.38] (28)	2.29 [1.53,3.05] (41)	1.96 [1.69,2.23] (231)	2.22 [1.93,2.51] (256)
Stroke, SE, or vascular death	9.77 [4.63,14.91] (18)	11.87 [6.81,16.93]	4.42 [3.34,5.50] (71)	4.64 [3.58,5.70] (81)	4.16 [3.77,4.55] (478)	4.47 [4.06,4.88] (504)
Stroke, SE, vascular death, MI	10.37 [5.07,15.67] (19)	13.75 [8.23,19.27] (26)	5.43 [4.23,6.63] (86)	5.99 [4.77,7.21] (103)	4.81 [4.39,5.23] (549)	5.17 [4.73,5.61] (579)
Stroke	4.74 [1.11,8.37] (9)	2.75 [0.22,5.28]	1.45 [0.82,2.08] (24)	1.95 [1.25,2.65] (35)	1.86 [1.60,2.12] (219)	2.07 [1.79,2.35] (239)
All-cause death	9.06 [4.26,13.86]	13.28 [8.06,18.50] (26)	4.88 [3.76,6.00] (78)	4.92 [3.84,6.00] (86)	4.19 [3.80,4.58] (482)	4.60 [4.19,5.01] (520)
Safety outcomes		~ /	~ /	~ /		
Major or NMCR bleeding	26.22 [16.51,35.93] (28)	22.90 [14.84,30.96] (31)	19.30 [16.75,21.85] (220)	16.17 [13.94,18.40] (202)	14.19 [13.39,14.99] (1222)	14.14 [13.34,14.94] (1209)
Major bleeding	9.90 [4.30,15.50] (12)	5.82 [2.02,9.62] (9)	5.95 [4.61,7.29] (76)	3.88 [2.85,4.91] (55)	3.22 [2.86,3.58] (307)	3.33 [2.96,3.70] (318)
Gastrointestinal bleeding	4.12 [0.51,7.73] (5)	1.94 [-0.26,4.14] (3)	2.89 [1.96,3.82] (37)	3.88 [2.85,4.91] (55)	3.22 [2.86,3.58] (307)	3.33 [2.96,3.70] (318)
Intracranial hemorrhage	1.53 [0,3.65] (2)	1.28 [0,3.06] (2)	0.84 [0.35,1.33] (11)	0.69 [0.26,1.12] (10)	0.43 [0.30,0.56] (42)	0.74 [0.57,0.91] (72)

Event rates are unadjusted. All abbreviations can be found in Supplemental Table 1A.

Abbreviations: AS, aortic stenosis; MR or AR, mitral or aortic regurgitation; ITT, intention-to-treat; MI, myocardial infarction; NMCR, non-major clinically relevant; pt-years, patient-years; SE, systemic embolism; SVD, significant valve disease; CI, confidence interval.


1B. Interaction tests and treatment comparisons within subgroups.^{*}

Outcomes	P-value for test of	AS	MR or AR	No SVD
	interaction between	rivaroxaban vs.	rivaroxaban vs.	rivaroxaban vs.
	treatment and	warfarin	warfarin	warfarin
	SVD subtype	HR (95% CI)	HR (95% CI)	HR (95% CI)
Efficacy outcomes				
Stroke or SE	0.71			
Stroke, SE, or vascular death	0.63			
Stroke, SE, vascular death, or MI	0.42			
Stroke	0.49			
All-cause death	0.33			
Safety outcomes				
Major or NMCR bleeding	0.047	1.18 (0.70, 1.97)	1.32 (1.08, 1.60)	1.01 (0.93, 1.10)
Major bleeding	0.016	1.73 (0.73, 4.12)	1.63 (1.15, 2.31)	0.97 (0.83, 1.14)
Gastrointestinal bleeding	0.34			
Intracranial hemorrhage	0.24			

^{*}Hazard ratios are shown only where there was a significant interaction. The p-value for the test of interaction between treatment and subgroups was derived from a single overall test performed in each model to determine treatment effect differences among the three groups.


Abbreviations: see Supplemental Table 1.

Suppl. Figure 1. Primary efficacy endpoint by subgroup.




Primary efficacy endpoint (stroke or systemic embolism) by subgroup (unadjusted data). For results of detailed statistical analyses, see Table 3.

Suppl. Figure 2. Primary safety endpoint by SVD subtype.



Primary safety endpoint (major or NMCR bleeding) by SVD subtype. For results of detailed statistical analyses, see Table 3. NMCR, non-major clinically relevant; SVD, significant valve disease

Suppl. Figure 3. Primary safety endpoint by SVD subtype and randomized treatment.



Primary safety endpoint (major or NMCR bleeding) by SVD subtype and randomized treatment. For results of detailed statistical analyses, see Supplemental Table 1. AS, aortic stenosis; NMCR, non-major clinically relevant; SVD, significant valve disease